Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714854 | 0.97 | KMT2A (0.57) | KMT2AMEN1MAPTGAATP53 | |
| SCHEMBL14739660 | 0.93 | MEN1 (0.54) | KMT2AMEN1MAPTGAATP53 | |
| SCHEMBL2594688 | 0.80 | SLC6A4 (0.43) | ALDH1A1RHEB | |
| SCHEMBL14753482 | 0.80 | MAPT (0.43) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL14740366 | 0.79 | ALDH1A1 (0.47) | KMT2AMEN1MAPTTP53ALDH1A1 | |
| SCHEMBL7706342 | 0.78 | RHEB (0.38) | KMT2AMEN1ALDH1A1RHEB | |
| SCHEMBL14738840 | 0.78 | MEN1 (0.40) | KMT2AMEN1MAPTGAATP53 | |
| SCHEMBL14753481 | 0.78 | ALDH1A1 (0.48) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL2595477 | 0.77 | TUBB4A (0.54) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL7705194 | 0.77 | RHEB (0.39) | KMT2AMEN1ALDH1A1RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | claimed |
| CN-102917707-A | Azaindole derivatives useful as modulators of FAAH | MERCK SHARP & DOHME | 2013-02-06 | — | — | CN | claimed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011140164-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, IDO1 | KMT2A 550/4885MEN1 3056/4885MAPT 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.